[1] Xavier RJ,Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease [J].Nature,2007,448(7152):427-434.[2] Leung RK,Whittaker PA.RNA interference: From gene silencingto gene-specific therapeutics [J].Pharmacol Ther,2005,107(2):222-239.[3] Zhang B,Wu T,Chen M,et al.The CD40/CD40L system: a new therapeutic target for disease [J].Immunol Lett,2013,153(1/2):58-61.[4] Danese S,Scaldaferri F,Vetrano S,et al.Critical role of the CD40-CD40-ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease [J].Gut,2007,56(9): 1248-1256.[5] LI ZY,Mao H,Kallick DA,et al.The effects of thiophosphate substitutions on native siRNA gene silencing [J].Biochem Bioph Res Commun,2005,329(3):1026-1030.[6] Jurjus AR,Khoury NN,Reimund JM.Animal models of inflammatory bowel disease [J].J Pharmacol Toxicol Methods,2004,50(2):81-92.[7] Globig AM,Hennecke N,Martin B,et al.Comprehensive intestinal T helper cell profiling reveals specific accumulation of IFN-γ+IL-17+coproducing CD4+ T cells in active inflammatory bowel disease [J].Inflamm Bowel Dis,2014,20(12):2321-2329.[8] Wilson MS,Ramalingam TR,Rivollier A,et al.Colitis and intestinal inflammation in IL-10-/- mice results from IL-13Rα2-mediated attenuation of IL-13 activity [J].Gstroenterology,2011,140(1):254-264.[9] Sawada-Hase N,Kiyohara T,Miyagawa J,et al.An increased number of CD40-high monocytes in patients with Crohn's disease [J].Am J Gastroenterol,2000,95(6):1516-1523.[10] Daness S,Sans M,Fiocchi C.The CD40/CD40L costim ulatory pathway in inflammatory bowel disease [J].Gut,2004,53(7):1035-1043.[11] 付海峰,周文波,丁佑铭,等.经沉默免疫负调控基因技术处理的树突状细胞联同细胞毒性T淋巴细胞对HepG2细胞移植瘤的抑制作用[J].临床肝胆病杂志,2014,30(9):891-894.[12] 吴列秀,蔺淑梅,张 曦,等.接受恩替卡韦治疗的慢性乙型肝炎患者外周血单个核细胞B7-H1的动态变化[J].临床肝胆病杂志,2014,30(9):929-931. |